跳至主要内容
临床试验/CTRI/2018/05/013958
CTRI/2018/05/013958招募中未知

Effectiveness and Safety Profile of TNF alpha Inhibitors inRefractory Spondyloarthopathies: An Observational Study.

Department of Pharmacology Institute of Postgraduate Medical Education and Research Kolkata0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1. Adult patients of age between 18-60 years of either gender clinically diagnosed as cases of Ankylosing Spondylitis or Psoriatic arthritis who have been advised TNF alpha inhibitor (Infliximab or Adalimumab) therapy as per institutional treatment protocol.
  • 2. Patients who satisfy eligibility criteria for getting TNF alpha inhibitors.
  • 3. Subjects willing to give written informed consent and comply with study related instructions.

排除标准

  • 1. Patients of Ankylosing Spondylitis or Psoriatic arthritis having any clinical condition were TNF alpha inhibitor (Infliximab or Adalimumab) therapy is contraindicated.
  • 2. Subjects unwilling to give written informed consent and comply with study related instructions.

研究者

发起方
Department of Pharmacology Institute of Postgraduate Medical Education and Research Kolkata

相似试验